Stock Taper
NYXH
NYXOAH S.A.
NASDAQ
$1.60
▼ DOWN 2.44% (-0.04)

KEY STATISTICS

Market Cap$160.12 M
52w High$6.88
52w Low$1.26
Dividend Yield
Frequency
P/E-0.63
Volume164.06K
Shares Out.100.07M

COMPANY

LEADERSHIP

Olivier Taelman
CHIEF EXECUTIVE
Olivier Taelman

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 28, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
154

PRICE TARGET

Target High$7.00
Target Low$2.31
Target Median$3.50
Target Consensus$4.08

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$11.61M
NOV
5
THU

PRICE

$1.60 ▼ DOWN 2.44% (−$0.04)
$1.60$1.63$1.65$1.679:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM1.60

About Nyxoah S.A.

https://www.nyxoah.com ↗

Nyxoah S.A. is a Belgian medical tech company developing and commercializing the Genio system, a CE-marked hypoglossal neurostimulation therapy for treating moderate to severe obstructive sleep apnea.

INDUSTRY

Medical - Specialties

A PRODUCT NYXOAH S.A. IS KNOWN FOR

Genio system
Genio system

The Genio system is a leadless, battery-free implantable neurostimulation device that treats moderate to severe Obstructive Sleep Apnea by stimulating the hypoglossal nerve to maintain airway openness, offering an alternative for patients intolera...

COMPETITORS

Revenue by Geography

MapREGIONQ3-2022Q4-2022Q2-2023Q4-2023
GERMANY$15K $2.79M $1M
AUSTRIA$81K $41K
SWITZERLAND$167K $47K $23K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
HOLD 1
3 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
OABI$4.33COMPARE
PRE$20.20COMPARE
IVVD$1.00COMPARE
OSUR$3.88COMPARE
UTMD$71.55COMPARE
TARA$3.85COMPARE
STIM$3.00COMPARE
KRMD$3.21COMPARE